IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis

The IL-1 family member cytokine IL-36γ is recognised as key mediator in the immunopathology of psoriasis, hallmarks of which involve the activation of both resident and infiltrating inflammatory myeloid cells and aberrant angiogenesis. This research demonstrates a role for IL-36γ in both myeloid act...

Full description

Bibliographic Details
Main Authors: Charlie Bridgewood, Gareth W. Fearnley, Anna Berekmeri, Philip Laws, Tom Macleod, Sreenivasan Ponnambalam, Martin Stacey, Anne Graham, Miriam Wittmann
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-02-01
Series:Frontiers in Immunology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2018.00200/full
id doaj-18b2841b2c65416fa826a005d1348c64
record_format Article
spelling doaj-18b2841b2c65416fa826a005d1348c642020-11-24T23:58:01ZengFrontiers Media S.A.Frontiers in Immunology1664-32242018-02-01910.3389/fimmu.2018.00200305217IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates AngiogenesisCharlie Bridgewood0Gareth W. Fearnley1Anna Berekmeri2Anna Berekmeri3Philip Laws4Philip Laws5Tom Macleod6Sreenivasan Ponnambalam7Martin Stacey8Anne Graham9Miriam Wittmann10Miriam Wittmann11Miriam Wittmann12Centre of Skin Sciences, School of Chemistry and Biosciences, University of Bradford, Bradford, United KingdomEndothelial Cell Biology Unit, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomDepartment of Dermatology, Chapel Allerton Hospital, Leeds, United KingdomFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomDepartment of Dermatology, Chapel Allerton Hospital, Leeds, United KingdomNational Institute of Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Chapel Allerton Hospital, Leeds, United KingdomFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomEndothelial Cell Biology Unit, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomFaculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United KingdomBiomedical Sciences, School of Chemistry and Biosciences, University of Bradford, Bradford, United KingdomCentre of Skin Sciences, School of Chemistry and Biosciences, University of Bradford, Bradford, United KingdomNational Institute of Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Chapel Allerton Hospital, Leeds, United KingdomLeeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United KingdomThe IL-1 family member cytokine IL-36γ is recognised as key mediator in the immunopathology of psoriasis, hallmarks of which involve the activation of both resident and infiltrating inflammatory myeloid cells and aberrant angiogenesis. This research demonstrates a role for IL-36γ in both myeloid activation and angiogenesis. We show that IL-36γ induces the production of psoriasis-associated cytokines from macrophages (IL-23 and TNFα) and that this response is enhanced in macrophages from psoriasis patients. This effect is specific for IL-36γ and could not be mimicked by other IL-1 family cytokines such as IL-1α. IL-36γ was also demonstrated to induce endothelial tube formation and branching, in a VEGF-A-dependent manner. Furthermore, IL-36γ-stimulated macrophages potently activated endothelial cells and led to increased adherence of monocytes, effects that were markedly more pronounced for psoriatic macrophages. Interestingly, regardless of stimulus, psoriasis monocytes showed increased adherence to both the stimulated and unstimulated endothelium when compared with monocytes from healthy individuals. Collectively, these findings show that IL-36γ has the potential to enhance endothelium directed leucocyte infiltration into the skin and strengthen the IL-23/IL-17 pathway adding to the growing evidence of pathogenetic roles for IL-36γ in psoriatic responses. Our findings also point to a cellular response, which could potentially explain cardiovascular comorbidities in psoriasis in the form of endothelial activation and increased monocyte adherence.http://journal.frontiersin.org/article/10.3389/fimmu.2018.00200/fullpsoriasisIL-36γIL-23macrophagesmonocytesangiogenesis
collection DOAJ
language English
format Article
sources DOAJ
author Charlie Bridgewood
Gareth W. Fearnley
Anna Berekmeri
Anna Berekmeri
Philip Laws
Philip Laws
Tom Macleod
Sreenivasan Ponnambalam
Martin Stacey
Anne Graham
Miriam Wittmann
Miriam Wittmann
Miriam Wittmann
spellingShingle Charlie Bridgewood
Gareth W. Fearnley
Anna Berekmeri
Anna Berekmeri
Philip Laws
Philip Laws
Tom Macleod
Sreenivasan Ponnambalam
Martin Stacey
Anne Graham
Miriam Wittmann
Miriam Wittmann
Miriam Wittmann
IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
Frontiers in Immunology
psoriasis
IL-36γ
IL-23
macrophages
monocytes
angiogenesis
author_facet Charlie Bridgewood
Gareth W. Fearnley
Anna Berekmeri
Anna Berekmeri
Philip Laws
Philip Laws
Tom Macleod
Sreenivasan Ponnambalam
Martin Stacey
Anne Graham
Miriam Wittmann
Miriam Wittmann
Miriam Wittmann
author_sort Charlie Bridgewood
title IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
title_short IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
title_full IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
title_fullStr IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
title_full_unstemmed IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
title_sort il-36γ is a strong inducer of il-23 in psoriatic cells and activates angiogenesis
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2018-02-01
description The IL-1 family member cytokine IL-36γ is recognised as key mediator in the immunopathology of psoriasis, hallmarks of which involve the activation of both resident and infiltrating inflammatory myeloid cells and aberrant angiogenesis. This research demonstrates a role for IL-36γ in both myeloid activation and angiogenesis. We show that IL-36γ induces the production of psoriasis-associated cytokines from macrophages (IL-23 and TNFα) and that this response is enhanced in macrophages from psoriasis patients. This effect is specific for IL-36γ and could not be mimicked by other IL-1 family cytokines such as IL-1α. IL-36γ was also demonstrated to induce endothelial tube formation and branching, in a VEGF-A-dependent manner. Furthermore, IL-36γ-stimulated macrophages potently activated endothelial cells and led to increased adherence of monocytes, effects that were markedly more pronounced for psoriatic macrophages. Interestingly, regardless of stimulus, psoriasis monocytes showed increased adherence to both the stimulated and unstimulated endothelium when compared with monocytes from healthy individuals. Collectively, these findings show that IL-36γ has the potential to enhance endothelium directed leucocyte infiltration into the skin and strengthen the IL-23/IL-17 pathway adding to the growing evidence of pathogenetic roles for IL-36γ in psoriatic responses. Our findings also point to a cellular response, which could potentially explain cardiovascular comorbidities in psoriasis in the form of endothelial activation and increased monocyte adherence.
topic psoriasis
IL-36γ
IL-23
macrophages
monocytes
angiogenesis
url http://journal.frontiersin.org/article/10.3389/fimmu.2018.00200/full
work_keys_str_mv AT charliebridgewood il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT garethwfearnley il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT annaberekmeri il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT annaberekmeri il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT philiplaws il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT philiplaws il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT tommacleod il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT sreenivasanponnambalam il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT martinstacey il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT annegraham il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT miriamwittmann il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT miriamwittmann il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
AT miriamwittmann il36gisastronginducerofil23inpsoriaticcellsandactivatesangiogenesis
_version_ 1725452196134256640